{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T15:35:48Z","timestamp":1770996948880,"version":"3.50.1"},"reference-count":133,"publisher":"Elsevier","isbn-type":[{"value":"9780128136676","type":"print"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1016\/b978-0-12-813667-6.00009-7","type":"book-chapter","created":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T19:41:19Z","timestamp":1525376479000},"page":"379-406","source":"Crossref","is-referenced-by-count":11,"title":["Psoriasis vulgaris\u2014Pathophysiology of the disease and its classical treatment versus new drug delivery systems"],"prefix":"10.1016","author":[{"given":"Ana R.","family":"Fernandes","sequence":"first","affiliation":[]},{"given":"Carlos","family":"Martins-Gomes","sequence":"additional","affiliation":[]},{"given":"Antonello","family":"Santini","sequence":"additional","affiliation":[]},{"given":"Am\u00e9lia M.","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Eliana B.","family":"Souto","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"1\u20132","key":"10.1016\/B978-0-12-813667-6.00009-7_bib1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijpharm.2015.03.020","article-title":"Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: application of Box-Behnken design, in-vitro evaluation and in-vivo skin deposition study","volume":"485","author":"Abdelbary","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"Pt B","key":"10.1016\/B978-0-12-813667-6.00009-7_bib2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ejpb.2015.01.026","article-title":"Biopharmaceutical profile of pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular administration","volume":"95","author":"Abrego","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1\u20132","key":"10.1016\/B978-0-12-813667-6.00009-7_bib3","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ijpharm.2016.01.071","article-title":"Biopharmaceutical profile of hydrogels containing pranoprofen-loaded PLGA nanoparticles for skin administration: in vitro, ex vivo and in vivo characterization","volume":"501","author":"Abrego","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"1\u20132","key":"10.1016\/B978-0-12-813667-6.00009-7_bib4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0378-5173(01)00810-9","article-title":"Preparation and in vitro evaluation of liposomal\/niosomal delivery systems for antipsoriatic drug dithranol","volume":"228","author":"Agarwal","year":"2001","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/B978-0-12-813667-6.00009-7_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/21691401.2013.832683","article-title":"Capsaicin delivery into the skin with lipidic nanoparticles for the treatment of psoriasis","volume":"43","author":"Agrawal","year":"2015","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"5","key":"10.1016\/B978-0-12-813667-6.00009-7_bib6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2230.2012.04360.x","article-title":"Modifiable lifestyle factors associated with metabolic syndrome in patients with psoriasis","volume":"37","author":"Ahdout","year":"2012","journal-title":"Clin. Exp. Dermatol."},{"issue":"6","key":"10.1016\/B978-0-12-813667-6.00009-7_bib7","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1517\/14712598.2014.900541","article-title":"The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial","volume":"14","author":"Al-Mutairi","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"issue":"13","key":"10.1016\/B978-0-12-813667-6.00009-7_bib8","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1084\/jem.20151093","article-title":"Melanocyte antigen triggers autoimmunity in human psoriasis","volume":"212","author":"Arakawa","year":"2015","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/B978-0-12-813667-6.00009-7_bib9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000343607","article-title":"Ultrasonographic assessment of nail in psoriatic disease shows a link between onychopathy and distal interphalangeal joint extensor tendon enthesopathy","volume":"225","author":"Aydin","year":"2012","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/B978-0-12-813667-6.00009-7_bib10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4103\/2230-973X.85963","article-title":"Nanocarrier-based hydrogel of betamethasone dipropionate and salicylic acid for treatment of psoriasis","volume":"1","author":"Baboota","year":"2011","journal-title":"Int. J. Pharm. Investig."},{"issue":"3","key":"10.1016\/B978-0-12-813667-6.00009-7_bib11","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1208\/s12249-011-9661-7","article-title":"Microparticulate based topical delivery system of clobetasol propionate","volume":"12","author":"Badilli","year":"2011","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/B978-0-12-813667-6.00009-7_bib12","first-page":"124","article-title":"Nanoparticles for gene delivery to retinal pigment epithelial cells","volume":"11","author":"Bejjani","year":"2005","journal-title":"Mol. Vis."},{"issue":"4","key":"10.1016\/B978-0-12-813667-6.00009-7_bib13","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.rdc.2015.07.013","article-title":"Etiology and pathogenesis of psoriasis","volume":"41","author":"Boehncke","year":"2015","journal-title":"Rheum. Dis. Clin. North Am."},{"issue":"9997","key":"10.1016\/B978-0-12-813667-6.00009-7_bib14","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/B978-0-12-813667-6.00009-7_bib15","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.2174\/1381612822666160603015436","article-title":"Microemulsion and microemulsion-based gels for topical antifungal therapy with phytochemicals","volume":"22","author":"Boonme","year":"2016","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/B978-0-12-813667-6.00009-7_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ad.2012.08.003","article-title":"Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications","volume":"105","author":"Carrascosa","year":"2014","journal-title":"Actas Dermosifiliogr."},{"issue":"7","key":"10.1016\/B978-0-12-813667-6.00009-7_bib17","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ad.2013.01.003","article-title":"Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology","volume":"104","author":"Carretero","year":"2013","journal-title":"Actas Dermosifiliogr."},{"issue":"1\u20132","key":"10.1016\/B978-0-12-813667-6.00009-7_bib18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bbamem.2004.01.006","article-title":"Hydrocortisone and dexamethasone in very deformable drug carriers have increased biological potency, prolonged effect, and reduced therapeutic dosage","volume":"1663","author":"Cevc","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"issue":"Suppl 1","key":"10.1016\/B978-0-12-813667-6.00009-7_bib19","doi-asserted-by":"crossref","first-page":"E1969","DOI":"10.1002\/hed.24361","article-title":"Pattern of lymph node metastasis in hypopharyngeal squamous cell carcinoma and indications for level VI lymph node dissection","volume":"38","author":"Chung","year":"2016","journal-title":"Head Neck"},{"issue":"8","key":"10.1016\/B978-0-12-813667-6.00009-7_bib20","first-page":"834","article-title":"Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis","volume":"49","author":"Clemons","year":"2011","journal-title":"Med. Mycol."},{"issue":"1","key":"10.1016\/B978-0-12-813667-6.00009-7_bib21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1530\/eje.1.02057","article-title":"Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines","volume":"154","author":"Corbetta","year":"2006","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"10.1016\/B978-0-12-813667-6.00009-7_bib22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1517\/17425240802712590","article-title":"Nanostructured lipid carrier-based hydrogel formulations for drug delivery: a comprehensive review","volume":"6","author":"Doktorovova","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"issue":"1","key":"10.1016\/B978-0-12-813667-6.00009-7_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2014.02.005","article-title":"Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers\u2014a systematic review of in vitro data","volume":"87","author":"Doktorovova","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/B978-0-12-813667-6.00009-7_bib24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ejpb.2016.08.001","article-title":"Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: current evidence from in vitro and in vivo evaluation","volume":"108","author":"Doktorovova","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/B978-0-12-813667-6.00009-7_bib25","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jconrel.2007.08.005","article-title":"Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes","volume":"123","author":"Dubey","year":"2007","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/B978-0-12-813667-6.00009-7_bib26","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1056\/NEJM200107263450403","article-title":"Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes","volume":"345","author":"Ellis","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/B978-0-12-813667-6.00009-7_bib27","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ejpb.2008.05.008","article-title":"Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC)","volume":"70","author":"Fang","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"3","key":"10.1016\/B978-0-12-813667-6.00009-7_bib28","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1046\/j.1365-2133.2003.05475.x","article-title":"Improved risk-benefit ratio for topical triamcinolone acetonide in Transfersome in comparison with equipotent cream and ointment: a randomized controlled trial","volume":"149","author":"Fesq","year":"2003","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/B978-0-12-813667-6.00009-7_bib29","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/1203475415586332","article-title":"The relationship of obesity with the severity of psoriasis: a systematic review","volume":"19","author":"Fleming","year":"2015","journal-title":"J. Cutan. Med. Surg."},{"key":"10.1016\/B978-0-12-813667-6.00009-7_bib30","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1146\/annurev-med-051914-021944","article-title":"Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseases","volume":"67","author":"Fragoulis","year":"2016","journal-title":"Annu. Rev. Med."},{"issue":"4","key":"10.1016\/B978-0-12-813667-6.00009-7_bib31","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s11926-014-0414-y","article-title":"The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment","volume":"16","author":"Frleta","year":"2014","journal-title":"Curr. Rheumatol. Rep."},{"issue":"9","key":"10.1016\/B978-0-12-813667-6.00009-7_bib32","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/B978-0-12-813667-6.00009-7_bib33","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4330\/wjc.v8.i2.120","article-title":"Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: three different diseases on a unique background","volume":"8","author":"Ganzetti","year":"2016","journal-title":"World J. Cardiol."},{"issue":"12","key":"10.1016\/B978-0-12-813667-6.00009-7_bib34","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/archderm.141.12.1537","article-title":"Prevalence and treatment of psoriasis in the United Kingdom: a population-based study","volume":"141","author":"Gelfand","year":"2005","journal-title":"Arch. Dermatol."},{"issue":"5","key":"10.1016\/B978-0-12-813667-6.00009-7_bib35","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3945\/ajcn.2008.26427","article-title":"Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial","volume":"88","author":"Gisondi","year":"2008","journal-title":"Am. J. Clin. Nutr."},{"issue":"1","key":"10.1016\/B978-0-12-813667-6.00009-7_bib36","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1111\/j.1468-3083.2012.04450.x","article-title":"Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry","volume":"27","author":"Gisondi","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/B978-0-12-813667-6.00009-7_bib37","first-page":"1","article-title":"Management of moderate to severe psoriasis in patients with metabolic comorbidities","volume":"2","author":"Gisondi","year":"2015","journal-title":"Front. Med. (Lausanne)"},{"issue":"2","key":"10.1016\/B978-0-12-813667-6.00009-7_bib38","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/jps.22784","article-title":"Improved and safe transcorneal delivery of flurbiprofen by NLC and NLC-based hydrogels","volume":"101","author":"Gonzalez-Mira","year":"2012","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/B978-0-12-813667-6.00009-7_bib39","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/bjd.12636","article-title":"Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory","volume":"170","author":"Gordon","year":"2014","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/B978-0-12-813667-6.00009-7_bib40","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics","volume":"58","author":"Gottlieb","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/B978-0-12-813667-6.00009-7_bib41","doi-asserted-by":"crossref","first-page":"13065","DOI":"10.1038\/srep13065","article-title":"Formulation strategy for the delivery of cyclosporine A: comparison of two polymeric nanospheres","volume":"5","author":"Goyal","year":"2015","journal-title":"Sci. Rep."},{"issue":"9583","key":"10.1016\/B978-0-12-813667-6.00009-7_bib42","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/B978-0-12-813667-6.00009-7_bib43","first-page":"841","article-title":"[Erythrodermic psoriasis: epidemiological clinical and therapeutic features about 60 cases]","volume":"89","author":"Hawilo","year":"2011","journal-title":"Tunis. Med."},{"issue":"4","key":"10.1016\/B978-0-12-813667-6.00009-7_bib44","first-page":"361","article-title":"Rapid-onset skin rash. Guttate psoriasis","volume":"86","author":"Henley","year":"2012","journal-title":"Am. Fam. Physician"},{"issue":"52","key":"10.1016\/B978-0-12-813667-6.00009-7_bib45","doi-asserted-by":"crossref","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci. Transl. Med."},{"issue":"1\u20132","key":"10.1016\/B978-0-12-813667-6.00009-7_bib46","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jconrel.2005.02.026","article-title":"Role of zinc in formulation of PLGA\/PLA nanoparticles encapsulating betamethasone phosphate and its release profile","volume":"105","author":"Ishihara","year":"2005","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/B978-0-12-813667-6.00009-7_bib47","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2133.2008.08902.x","article-title":"Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin","volume":"160","author":"Johansen","year":"2009","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/B978-0-12-813667-6.00009-7_bib48","first-page":"233","article-title":"Clobetasol propionate solid lipid nanoparticles cream for effective treatment of eczema: formulation and clinical implications","volume":"43","author":"Kalariya","year":"2005","journal-title":"Indian J. Exp. Biol."},{"key":"10.1016\/B978-0-12-813667-6.00009-7_bib49","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-042915-103905","article-title":"Highly effective new treatments for psoriasis target the IL-23\/Type 17 T cell autoimmune axis","volume":"68","author":"Kim","year":"2017","journal-title":"Annu. Rev. Med."},{"issue":"1","key":"10.1016\/B978-0-12-813667-6.00009-7_bib50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/02652049809006832","article-title":"Delivery of hydrocortisone from liposomal suspensions to the hairless mouse skin following topical application under non-occlusive and occlusive conditions","volume":"15","author":"Kim","year":"1998","journal-title":"J. Microencapsul."},{"issue":"8","key":"10.1016\/B978-0-12-813667-6.00009-7_bib51","first-page":"510","article-title":"Topical administration of cyclosporin A in a solid lipid nanoparticle formulation","volume":"64","author":"Kim","year":"2009","journal-title":"Pharmazie"},{"issue":"2","key":"10.1016\/B978-0-12-813667-6.00009-7_bib52","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/archdermatol.2007.63","article-title":"Safety and efficacy of ABT-874, a fully human interleukin 12\/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial","volume":"144","author":"Kimball","year":"2008","journal-title":"Arch. Dermatol."},{"issue":"4","key":"10.1016\/B978-0-12-813667-6.00009-7_bib53","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2012.10901.x","article-title":"Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years","volume":"166","author":"Kimball","year":"2012","journal-title":"Br. J. Dermatol."},{"issue":"12","key":"10.1016\/B978-0-12-813667-6.00009-7_bib54","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/jdv.12046","article-title":"Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study","volume":"27","author":"Kimball","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"3","key":"10.1016\/B978-0-12-813667-6.00009-7_bib55","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ejpb.2012.04.005","article-title":"Calcipotriol delivery into the skin with PEGylated liposomes","volume":"81","author":"Knudsen","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"7551","key":"10.1016\/B978-0-12-813667-6.00009-7_bib56","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature14175","article-title":"Clinical improvement in psoriasis with specific targeting of interleukin-23","volume":"521","author":"Kopp","year":"2015","journal-title":"Nature"},{"issue":"5","key":"10.1016\/B978-0-12-813667-6.00009-7_bib57","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000056359","article-title":"Enhancement of the antiparakeratotic potency of calcitriol and tacalcitol in liposomal preparations in the mouse tail test","volume":"14","author":"Korbel","year":"2001","journal-title":"Skin Pharmacol. Appl. Skin Physiol."},{"issue":"5","key":"10.1016\/B978-0-12-813667-6.00009-7_bib58","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/ced.12841","article-title":"Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA","volume":"41","author":"Korman","year":"2016","journal-title":"Clin. Exp. Dermatol."},{"issue":"6","key":"10.1016\/B978-0-12-813667-6.00009-7_bib59","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa062382","article-title":"A human interleukin-12\/23 monoclonal antibody for the treatment of psoriasis","volume":"356","author":"Krueger","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/B978-0-12-813667-6.00009-7_bib60","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s13346-012-0060-8","article-title":"Suppression of cytokine gene expression and improved therapeutic efficacy of microemulsion-based tacrolimus cream for atopic dermatitis","volume":"2","author":"Lalan","year":"2012","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/B978-0-12-813667-6.00009-7_bib61","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.1038\/ncomms6621","article-title":"The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis","volume":"5","author":"Lande","year":"2014","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/B978-0-12-813667-6.00009-7_bib62","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/j.1468-3083.2012.04705.x","article-title":"Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12\/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis","volume":"27","author":"Langley","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"4","key":"10.1016\/B978-0-12-813667-6.00009-7_bib63","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/B978-0-12-813667-6.00009-7_bib64","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1021\/mp400639e","article-title":"Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: a targeted approach for the treatment of psoriasis","volume":"11","author":"Lapteva","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/B978-0-12-813667-6.00009-7_bib65","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jconrel.2014.09.021","article-title":"Targeted cutaneous delivery of ciclosporin A using micellar nanocarriers and the possible role of inter-cluster regions as molecular transport pathways","volume":"196","author":"Lapteva","year":"2014","journal-title":"J Control. Release"},{"issue":"1","key":"10.1016\/B978-0-12-813667-6.00009-7_bib66","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejpb.2012.05.011","article-title":"Tacrolimus-loaded ethosomes: physicochemical characterization and in vivo evaluation","volume":"82","author":"Li","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"3","key":"10.1016\/B978-0-12-813667-6.00009-7_bib67","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/bmc.2795","article-title":"Development and validation of a sensitive LC-MS\/MS method for determination of tacrolimus on dried blood spots","volume":"27","author":"Li","year":"2013","journal-title":"Biomed. Chromatogr."},{"issue":"10","key":"10.1016\/B978-0-12-813667-6.00009-7_bib68","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1084\/jem.20061308","article-title":"Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides","volume":"203","author":"Liang","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/B978-0-12-813667-6.00009-7_bib69","first-page":"117","article-title":"Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery","volume":"5","author":"Lin","year":"2010","journal-title":"Int. J. Nanomedicine"},{"issue":"1","key":"10.1016\/B978-0-12-813667-6.00009-7_bib70","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/1744666X.2016.1213631","article-title":"Co-morbidity in psoriasis: mechanisms and implications for treatment","volume":"13","author":"Lonnberg","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"1","key":"10.1016\/B978-0-12-813667-6.00009-7_bib71","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2340\/00015555-2171","article-title":"Genetic factors explain variation in the age at onset of psoriasis: a population-based twin study","volume":"96","author":"Lonnberg","year":"2016","journal-title":"Acta Derm. Venereol."},{"issue":"1","key":"10.1016\/B978-0-12-813667-6.00009-7_bib72","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jdermsci.2011.11.007","article-title":"Chemokine receptors in the pathogenesis and therapy of psoriasis","volume":"65","author":"Mabuchi","year":"2012","journal-title":"J. Dermatol. Sci."},{"issue":"6","key":"10.1016\/B978-0-12-813667-6.00009-7_bib73","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1155\/1996\/213596","article-title":"Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up","volume":"10","author":"Malatjalian","year":"1996","journal-title":"Can. J. Gastroenterol."},{"issue":"8","key":"10.1016\/B978-0-12-813667-6.00009-7_bib74","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1111\/jdv.13678","article-title":"Laser and light therapies for the treatment of nail psoriasis","volume":"30","author":"Maranda","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"3","key":"10.1016\/B978-0-12-813667-6.00009-7_bib75","first-page":"167","article-title":"Update on treatment of psoriatic arthritis","volume":"70","author":"Mease","year":"2012","journal-title":"Bull. NYU Hosp. Jt. Dis."},{"issue":"2","key":"10.1016\/B978-0-12-813667-6.00009-7_bib76","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00128071-200102020-00005","article-title":"Clobetasol propionate foam, 0.05%","volume":"2","author":"Melian","year":"2001","journal-title":"Am. J. Clin. Dermatol."},{"issue":"4","key":"10.1016\/B978-0-12-813667-6.00009-7_bib77","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jaad.2008.12.032","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies","volume":"60","author":"Menter","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/B978-0-12-813667-6.00009-7_bib78","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jaad.2009.08.026","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy","volume":"62","author":"Menter","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/B978-0-12-813667-6.00009-7_bib79","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jaad.2014.03.016","article-title":"Diet and psoriasis, part III: role of nutritional supplements","volume":"71","author":"Millsop","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"issue":"Suppl 2","key":"10.1016\/B978-0-12-813667-6.00009-7_bib80","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1468-3083.2011.03991.x","article-title":"Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity","volume":"25","author":"Montaudie","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"5","key":"10.1016\/B978-0-12-813667-6.00009-7_bib81","doi-asserted-by":"crossref","first-page":"C1013","DOI":"10.1152\/ajpcell.00475.2010","article-title":"Expression of TASK-2 and its upregulation by B cell receptor stimulation in WEHI-231 mouse immature B cells","volume":"300","author":"Nam","year":"2011","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"12","key":"10.1016\/B978-0-12-813667-6.00009-7_bib82","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/jdv.13354","article-title":"European S3-guidelines on the systemic treatment of psoriasis vulgaris--update 2015--short version--EDF in cooperation with EADV and IPC","volume":"29","author":"Nast","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"5","key":"10.1016\/B978-0-12-813667-6.00009-7_bib83","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/B978-0-12-813667-6.00009-7_bib84","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3109\/1061186X.2013.769106","article-title":"Comparison of PLGA and lecithin\/chitosan nanoparticles for dermal targeting of betamethasone valerate","volume":"21","author":"Ozcan","year":"2013","journal-title":"J. Drug Target."},{"issue":"6","key":"10.1016\/B978-0-12-813667-6.00009-7_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2014.08.039","article-title":"Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment","volume":"71","author":"Papp","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/B978-0-12-813667-6.00009-7_bib86","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/B978-0-12-813667-6.00009-7_bib87","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.colsurfb.2012.08.011","article-title":"Topical delivery of clobetasol propionate loaded microemulsion based gel for effective treatment of vitiligo: ex vivo permeation and skin irritation studies","volume":"102","author":"Patel","year":"2013","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"Suppl 2","key":"10.1016\/B978-0-12-813667-6.00009-7_bib88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2009.03389.x","article-title":"European S3-guidelines on the systemic treatment of psoriasis vulgaris","volume":"23","author":"Pathirana","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"2","key":"10.1016\/B978-0-12-813667-6.00009-7_bib89","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3109\/09546634.2011.607796","article-title":"Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study","volume":"24","author":"Patsatsi","year":"2013","journal-title":"J. Dermatolog. Treat."},{"issue":"7","key":"10.1016\/B978-0-12-813667-6.00009-7_bib90","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/ajhp\/57.7.645","article-title":"Pathophysiology and treatment of psoriasis","volume":"57","author":"Peters","year":"2000","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"1\u20132","key":"10.1016\/B978-0-12-813667-6.00009-7_bib91","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ijpharm.2014.10.067","article-title":"A new topical formulation for psoriasis: development of methotrexate-loaded nanostructured lipid carriers","volume":"477","author":"Pinto","year":"2014","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/B978-0-12-813667-6.00009-7_bib92","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1365-2133.1998.02122.x","article-title":"Renal function after 10 years\u2019 treatment with cyclosporin for psoriasis","volume":"138","author":"Powles","year":"1998","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/B978-0-12-813667-6.00009-7_bib93","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.chemphyslip.2014.11.004","article-title":"Development characterization and skin permeating potential of lipid based novel delivery system for topical treatment of psoriasis","volume":"186","author":"Pradhan","year":"2015","journal-title":"Chem. Phys. Lipids"},{"issue":"1","key":"10.1016\/B978-0-12-813667-6.00009-7_bib94","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3109\/21691401.2014.955105","article-title":"Influence of selected variables on fabrication of Triamcinolone acetonide loaded solid lipid nanoparticles for topical treatment of dermal disorders","volume":"44","author":"Pradhan","year":"2016","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"3","key":"10.1016\/B978-0-12-813667-6.00009-7_bib95","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1208\/s12249-015-0376-z","article-title":"Topical niosome gel of Zingiber cassumunar Roxb. extract for anti-inflammatory activity enhanced skin permeation and stability of compound D","volume":"17","author":"Priprem","year":"2016","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"10.1016\/B978-0-12-813667-6.00009-7_bib96","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.tvjl.2013.02.018","article-title":"Efficacy of a new topical cyclosporine A formulation in the treatment of atopic dermatitis in dogs","volume":"197","author":"Puigdemont","year":"2013","journal-title":"Vet. J."},{"issue":"1","key":"10.1016\/B978-0-12-813667-6.00009-7_bib97","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2174\/157016312799304516","article-title":"Insight into the biomarkers as the novel anti-psoriatic drug discovery tool: a contemporary viewpoint","volume":"9","author":"Rahman","year":"2012","journal-title":"Curr. Drug Discov. Technol."},{"issue":"4-5","key":"10.1016\/B978-0-12-813667-6.00009-7_bib98","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.autrev.2014.01.008","article-title":"Diagnosis and classification of psoriasis","volume":"13","author":"Raychaudhuri","year":"2014","journal-title":"Autoimmun. Rev."},{"issue":"3","key":"10.1016\/B978-0-12-813667-6.00009-7_bib99","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3109\/02652048.2010.546435","article-title":"Novel dithranol phospholipid microemulsion for topical application: development, characterization and percutaneous absorption studies","volume":"28","author":"Raza","year":"2011","journal-title":"J. Microencapsul."},{"issue":"1","key":"10.1016\/B978-0-12-813667-6.00009-7_bib100","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijpharm.2013.08.019","article-title":"Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti-psoriatic activity","volume":"456","author":"Raza","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/B978-0-12-813667-6.00009-7_bib101","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjd.12070","article-title":"Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study","volume":"168","author":"Rich","year":"2013","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/B978-0-12-813667-6.00009-7_bib102","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000334482","article-title":"Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study","volume":"223","author":"Rigopoulos","year":"2011","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/B978-0-12-813667-6.00009-7_bib103","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.soard.2014.03.025","article-title":"Psoriasis improvement after bariatric surgery","volume":"10","author":"Romero-Talamas","year":"2014","journal-title":"Surg. Obes. Relat. Dis."},{"issue":"3","key":"10.1016\/B978-0-12-813667-6.00009-7_bib104","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3109\/10837450.2012.712537","article-title":"Hydrocortisone-loaded poly(epsilon-caprolactone) nanoparticles for atopic dermatitis treatment","volume":"18","author":"Rosado","year":"2013","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/B978-0-12-813667-6.00009-7_bib105","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jconrel.2016.07.003","article-title":"Advances in psoriasis physiopathology and treatments: up to date of mechanistic insights and perspectives of novel therapies based on innovative skin drug delivery systems (ISDDS)","volume":"239","author":"Sala","year":"2016","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/B978-0-12-813667-6.00009-7_bib106","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/1061186021000038364","article-title":"Drug targeting by solid lipid nanoparticles for dermal use","volume":"10","author":"Santos Maia","year":"2002","journal-title":"J. Drug Target."},{"issue":"5","key":"10.1016\/B978-0-12-813667-6.00009-7_bib107","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3109\/10611869908996843","article-title":"Light and electron microscopic findings in a model of human cutaneous candidosis based on reconstructed human epidermis following the topical application of different econazole formulations","volume":"6","author":"Schaller","year":"1999","journal-title":"J. Drug Target."},{"issue":"4","key":"10.1016\/B978-0-12-813667-6.00009-7_bib108","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000324053","article-title":"Drug release and skin penetration from solid lipid nanoparticles and a base cream: a systematic approach from a comparison of three glucocorticoids","volume":"24","author":"Schlupp","year":"2011","journal-title":"Skin Pharmacol. Physiol."},{"issue":"1","key":"10.1016\/B978-0-12-813667-6.00009-7_bib109","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/ajcn\/54.1.26","article-title":"Estimation of extracellular and total body water by multiple-frequency bioelectrical-impedance measurement","volume":"54","author":"Segal","year":"1991","journal-title":"Am. J. Clin. Nutr."},{"issue":"3","key":"10.1016\/B978-0-12-813667-6.00009-7_bib110","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jconrel.2009.11.013","article-title":"Lecithin\/chitosan nanoparticles of clobetasol-17-propionate capable of accumulation in pig skin","volume":"142","author":"Senyigit","year":"2010","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/B978-0-12-813667-6.00009-7_bib111","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.mcna.2015.08.001","article-title":"Psoriasis and cardiovascular disease","volume":"99","author":"Shahwan","year":"2015","journal-title":"Med. Clin. North Am."},{"issue":"2","key":"10.1016\/B978-0-12-813667-6.00009-7_bib112","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ejpb.2010.06.014","article-title":"Enhanced topical delivery and anti-inflammatory activity of methotrexate from an activated nanogel","volume":"76","author":"Singka","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"3","key":"10.1016\/B978-0-12-813667-6.00009-7_bib113","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/ajcn\/52.3.405","article-title":"Reassessment of body mass indices","volume":"52","author":"Smalley","year":"1990","journal-title":"Am. J. Clin. Nutr."},{"issue":"4","key":"10.1016\/B978-0-12-813667-6.00009-7_bib114","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaci.2014.01.025","article-title":"Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis","volume":"133","author":"Sofen","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"issue":"12","key":"10.1016\/B978-0-12-813667-6.00009-7_bib115","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1517\/17425247.2014.938634","article-title":"Solid lipid nanoparticles-loaded topical gel containing combination drugs: an approach to offset psoriasis","volume":"11","author":"Sonawane","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/B978-0-12-813667-6.00009-7_bib116","series-title":"Skin Anatomy and Physiology Research Developments, Human Anatomy and Physiology Series","first-page":"1","article-title":"Lipid nanoparticles (LP) versus nanoemulsions (NE) for topical pharmaceuticals","author":"Souto","year":"2009"},{"issue":"1","key":"10.1016\/B978-0-12-813667-6.00009-7_bib117","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejpb.2004.02.015","article-title":"Evaluation of the physical stability of SLN and NLC before and after incorporation into hydrogel formulations","volume":"58","author":"Souto","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/B978-0-12-813667-6.00009-7_bib118","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ijpharm.2012.01.045","article-title":"Physico-chemical characteristics of methotrexate-entrapped oleic acid-containing deformable liposomes for in vitro transepidermal delivery targeting psoriasis treatment","volume":"427","author":"Srisuk","year":"2012","journal-title":"Int. J. Pharm."},{"issue":"11","key":"10.1016\/B978-0-12-813667-6.00009-7_bib119","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1038\/jid.2012.184","article-title":"Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis","volume":"132","author":"Suarez-Farinas","year":"2012","journal-title":"J. Invest. Dermatol."},{"issue":"4-5","key":"10.1016\/B978-0-12-813667-6.00009-7_bib120","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.autrev.2014.01.050","article-title":"The IL-23\/IL-17 axis in psoriatic arthritis","volume":"13","author":"Suzuki","year":"2014","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/B978-0-12-813667-6.00009-7_bib121","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/11532060-000000000-00000","article-title":"Inverse psoriasis: case presentation and review","volume":"12","author":"Syed","year":"2011","journal-title":"Am. J. Clin. Dermatol."},{"issue":"225","key":"10.1016\/B978-0-12-813667-6.00009-7_bib122","first-page":"169","article-title":"[Influence of exogenous and endogenous factors on the course of psoriasis]","volume":"38","author":"Trojacka","year":"2015","journal-title":"Pol. Merkur. Lekarski."},{"issue":"4","key":"10.1016\/B978-0-12-813667-6.00009-7_bib123","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/febs.13904","article-title":"Chronic systemic inflammation originating from epithelial tissues","volume":"284","author":"Uluckan","year":"2017","journal-title":"FEBS J."},{"key":"10.1016\/B978-0-12-813667-6.00009-7_bib124","series-title":"Carrier-Mediated Dermal Delivery: Applications in the Prevention and Treatment of Skin Disorders","first-page":"323","article-title":"Archaeosomes for skin injuries","author":"Vazzana","year":"2017"},{"issue":"12","key":"10.1016\/B978-0-12-813667-6.00009-7_bib125","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1001\/2013.jamadermatol.80","article-title":"Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis","volume":"148","author":"Viguier","year":"2012","journal-title":"Arch. Dermatol."},{"issue":"4","key":"10.1016\/B978-0-12-813667-6.00009-7_bib126","first-page":"468","article-title":"Psoriasis and Metabolic Syndrome\u2013scientific evidence and therapeutic implications","volume":"7","author":"Voiculescu","year":"2014","journal-title":"J. Med. Life."},{"issue":"12","key":"10.1016\/B978-0-12-813667-6.00009-7_bib127","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nrrheum.2010.157","article-title":"Psoriasis: what we have learned from mouse models","volume":"6","author":"Wagner","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"issue":"6","key":"10.1016\/B978-0-12-813667-6.00009-7_bib128","doi-asserted-by":"crossref","first-page":"e007526","DOI":"10.1136\/bmjopen-2014-007526","article-title":"Acupuncture for psoriasis: protocol for a systematic review","volume":"5","author":"Wang","year":"2015","journal-title":"BMJ Open"},{"issue":"7","key":"10.1016\/B978-0-12-813667-6.00009-7_bib129","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1136\/adc.2005.085522","article-title":"Measuring body composition","volume":"91","author":"Wells","year":"2006","journal-title":"Arch. Dis. Child"},{"issue":"12","key":"10.1016\/B978-0-12-813667-6.00009-7_bib130","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.3760\/cma.j.issn.0366-6999.20140518","article-title":"Effects of tacrolimus and cyclosporine treatment on metabolic syndrome and cardiovascular risk factors after renal transplantation: a meta-analysis","volume":"127","author":"Xue","year":"2014","journal-title":"Chin. Med. J. (Engl)"},{"issue":"3","key":"10.1016\/B978-0-12-813667-6.00009-7_bib131","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/jps.22329","article-title":"Percutaneous permeation of betamethasone 17-valerate incorporated in lipid nanoparticles","volume":"100","author":"Zhang","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/B978-0-12-813667-6.00009-7_bib132","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2147\/IJN.S57314","article-title":"Evaluation of psoralen ethosomes for topical delivery in rats by using in vivo microdialysis","volume":"9","author":"Zhang","year":"2014","journal-title":"Int. J. Nanomedicine"},{"issue":"2","key":"10.1016\/B978-0-12-813667-6.00009-7_bib133","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.nano.2009.08.002","article-title":"Pharmaceutical foams: are they the answer to the dilemma of topical nanoparticles?","volume":"6","author":"Zhao","year":"2010","journal-title":"Nanomedicine"}],"container-title":["Design of Nanostructures for Versatile Therapeutic Applications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780128136676000097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780128136676000097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T13:44:19Z","timestamp":1720273459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780128136676000097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9780128136676"],"references-count":133,"URL":"https:\/\/doi.org\/10.1016\/b978-0-12-813667-6.00009-7","relation":{},"subject":[],"published":{"date-parts":[[2018]]}}}